Doctor Anywhere: A Health Platform Hides Complexity — It Never Removes It

01

The business model

The on-demand healthcare model puts a full care pathway behind one app: a video consultation within minutes, medicine delivered to the door, in-person care booked when needed.

The record. Founded in Singapore in 2016 by Lim Wai Mun — begun as a side project to reach homebound elderly patients — Doctor Anywhere launched in 2017 and grew to serve more than 2.8 million users across six Southeast Asian markets through a network of some 2,800 clinicians. Its S$88 million Series C in 2021 was among the largest healthtech rounds Southeast Asia had seen, and its payer partnerships include Prudential and Allianz.

How the model works. Follow one consultation through the machine. A patient — almost always covered by an employer or insurer contract rather than paying retail — opens the app and requests a doctor. The platform’s hardest problem fires immediately: matching that unpredictable request against a credentialed doctor who is licensed in that patient’s country, available now, and appropriate for the complaint. The consultation produces an e-prescription, which flows to the platform’s pharmacy operation for same-day delivery — a second margin on the same interaction — and the record flows onward to the insurer for claims. Revenue stacks in three layers: the consultation fee, the pharmacy margin, and the anchor underneath both — per-member B2B contracts with insurers and employers who pay for their populations to have digital-first access. The cost side is dominated by supply liquidity: enough doctors, in enough specialties, in every licensed market, at every hour the promise covers. And each market multiplies the compliance build — licensing, credentialing, clinical governance, health-data rules — because the app is one product, but the regulated operation behind it must be rebuilt per country.

• Earns from: per-member institutional contracts as the anchor; consultation fees and pharmacy margin stacked on top of each interaction. – Wins on: one clean patient experience hiding a fully regulated, per-market operation. – The tension: unpredictable demand against credentialed supply, in minutes, without ever compromising the standard of care.

Where this model fails. Consumer-first launches, again — retail health customers are expensive to acquire and rarely cover their own service cost; the durable economics were always institutional. Supply liquidity gaps — a patient who waits forty minutes for a “consultation in minutes” churns and tells their HR department. And multi-market ambition priced as marketing: each new country is a regulatory operation, and operators who discover that cost after committing capital tend to retreat from markets they announced.

02

What the case taught us

The working record stays sealed; the learning is shared.

• Hide complexity — never remove it. The compliance, credentialing, and clinical governance layers stay heavy, and they must. The architecture decides only whether the patient ever feels their weight. Platforms fail in two symmetrical ways: exposing the complexity (a patient navigating clinical bureaucracy leaves) or deleting it (a platform that trims governance for speed eventually meets the regulator).
• The B2B contract is the business; the app is the proof. Insurers and employers fund the model’s economics; the consumer experience exists to make the institutional promise true. Founders who read app-store downloads as the business build the wrong company — the durable revenue was always institutional, and institutions buy outcomes and coverage, not interfaces.
• The platform is one product; the operation is a portfolio. Each market means a new regulated build — licensing, clinical partnerships, data rules. The honest planning question is never “how fast can we launch markets” but “how many regulated operations can we run well at once.” Growth capital in this category buys operations, not marketing.

A health platform’s job is to hide complexity from the patient — never to remove it from the system.

03

Chitrangana’s transformation advisory

“On-demand” is a transitional word. By 2030, this model’s centre of gravity moves from episodic consultations to continuous care — wearables and home diagnostics streaming signals, AI monitoring the stream, the platform intervening before the patient would have thought to book anything. The commercial logic strengthens rather than changes: insurers and employers, already the payers, will pay far more for prevented claims than for delivered consultations. Our advisory to operators of this model, in order:

1. Reweight the business toward the institutional book. Audit what share of revenue and margin the B2B contracts actually carry, and negotiate the next generation of those contracts on outcomes — adherence, early intervention, avoided claims — because that is what continuity gets paid for, and consultation-count contracts will be commoditised first.
2. Build the monitoring-to-intervention loop on one condition before all conditions. Pick a chronic pathway where the data, the clinical protocol, and the payer’s savings are all measurable — prove the continuous-care loop end to end there, with governed AI escalation, before generalising. A working loop on one condition beats a roadmap for twenty.
3. Consolidate the regulated operations before adding markets. Standardise the per-market compliance build into a repeatable playbook — licensing, credentialing, data — so each future market is an execution, not an invention. Continuity of care will raise the regulatory bar, not lower it.

Putting an AI layer in the middle of a regulated care pathway — where escalation design carries clinical and legal weight — is the discipline of AI Consulting; repositioning an episodic platform into a continuity business without breaking the contracts funding it today is Business Transformation in its purest form.

The strongest health platforms will be paid for the consultations that never needed to happen.

Chitrangana